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T he Hancock II bioprosthesis (Medtronic Inc,Minneapolis, Minn) differs from its predecessors in
several aspects: the porcine aortic root is fixed with a
buffered solution of 0.625% glutaraldehyde in two
stages, an initial stage of low pressure and a late stage
of physiologic pressure; the stent is made of Delrin
resin (DuPont, Wilmington, Del) and was redesigned to
minimize mechanical stress on the cusps; and the tissue
is treated with sodium dodecyl-sulfate to retard calcifi-
cation.1 The sewing ring of the bioprosthesis for aortic
valve replacement (AVR) was designed for implanta-
tion in a supra-annular position. The first clinical
Objective: To review the late clinical outcomes of patients who had isolated
aortic or mitral valve replacement with the Hancock II bioprosthesis.
Methods: From 1982 to 1994, 670 patients underwent isolated aortic valve
replacement and 310 underwent isolated mitral valve replacement with
the Hancock II bioprosthesis (Medtronic Inc, Minneapolis, Minn). Mean
age was 65 ± 12 years in both groups. Most patients were in New York
Heart Association functional classes III or IV, and concomitant coronary
artery disease was present in 44% of patients in the aortic valve group and
41% of patients in the mitral valve group. Patients were followed up
prospectively at periodic intervals. Mean follow-up was 87 ± 45 months
in the aortic valve group and 83 ± 50 months in the mitral valve group,
and it was 99% complete.
Results: Actuarial survival at 15 years was 47% ± 3% in the aortic valve
group and 30% ± 5% in the mitral valve group. Older age, advanced func-
tional class, impaired left ventricular function, active endocarditis, and coro-
nary artery disease were independent predictors of late death. The freedom
from thromboembolic complications at 15 years was 83% ± 3% in the aor-
tic and 87% ± 3% in the mitral valve group. The freedom from infective
endocarditis at 15 years was 96% ± 1% in the aortic and 91% ± 1% in the
mitral valve group. At 15 years, the actuarial and actual freedom from struc-
tural valve deterioration was 81% ± 5% and 90% ± 3%, respectively, in the
aortic group and 66% ± 6% and 83% ± 3%, respectively, in the mitral group.
Younger age, mitral valve position, and poor ventricular function were inde-
pendent predictors of structural valve deterioration. The freedom from repeat
valve replacement at 15 years was 77% ± 5% in the aortic group and 69% ±
6% in the mitral. The vast majority of patients had functional improvement
after valve replacement. 
Conclusions: The Hancock II bioprosthesis has provided good clinical out-
comes and is a durable valve, particularly in the aortic position in older
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implantation of this valve occurred in September 1982
in Toronto. Although this bioprosthetic valve has been
extensively used in Canada and Europe, it was only
recently approved for clinical use in the United States.
The following report updates late clinical outcomes in
patients who had AVR or mitral valve replacement
(MVR) with the Hancock II bioprosthesis. 
Patients and methods
Between September 1982 and December 1994, 670 con-
secutive patients underwent isolated AVR (AVR group), 310
patients underwent isolated MVR (MVR group), and 148
patients underwent aortic and mitral valve surgery with the
Hancock II bioprosthesis at Toronto Western Hospital (1982
through 1989) and Toronto General Hospital (1989 through
1994). Because of the relatively small number of patients
undergoing double valve surgery (many patients had one
valve replaced and the other repaired), this group was exclud-
ed from this analysis.
Tables I and II summarize the preoperative clinical profiles
and the operative variables of each group. Mean age was 65
± 12 years in AVR patients and 65 ± 11 years in MVR
patients. Although the 980 operative procedures were divided
among 12 surgeons, 2 surgeons performed approximately
three quarters of the operations (493 AVR: 74%; 243 MVR:
78%). Patients who underwent mitral valve repair and AVR
with a Hancock II bioprosthesis were excluded from the AVR
group. Patients with significant coronary artery disease
(CAD) on preoperative angiography underwent concomitant
coronary artery bypass graft surgery.
All patients were entered into a database at the time of the
operation and were followed up prospectively at periodic
intervals. The recent follow-up was conducted by either
mailed questionnaire or telephone interview. When patients
could not be contacted via such methods, follow-up was
obtained from a family physician. Follow-up of all patients
was 99% complete at a mean interval of 87 ± 45 months
(range 0-201 months) in the AVR group and 83 ± 50 months
(range 0-195 months) in the MVR group. Six patients were
lost to follow-up, 4 from the AVR group and 2 from the MVR
group. 
To minimize transvalvular gradients, we attempted to
match patient body surface area to bioprosthetic size using
guidelines based on the hemodynamic performance of the
Hancock II bioprosthesis.2,3 To accomplish this, we had to
enlarge the aortic anulus with a patch in 125 (19%) patients
undergoing AVR. In general, patch enlargement enabled
insertion of valves 1 to 2 sizes larger than would have other-
wise been possible without enlargement.
From 1985 to 1989, all patients undergoing bioprosthetic
valvular replacement at the two hospitals were discharged
from the hospital on a regimen of daily warfarin sodium for
the first 3 months postoperatively, followed by lifelong
aspirin therapy. This practice was discontinued in 1990, after
which only patients with bioprosthetic MVR were given war-
farin for the first 3 postoperative months. 
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Operative survivors underwent at least one echocardio-
graphic evaluation during the first postoperative year, along
with additional evaluations in the event of cardiac or valve-
related complications. Postoperative complications were
prospectively monitored and analyzed according to guide-
lines set forth by The American Association for Thoracic
Surgery.4
Outcomes. The primary outcome in this analysis was all-
cause mortality. Cause of death was established from hospi-
tal records or autopsy reports when available. Operative death
was defined as any death in the hospital or at home within 30
days after the operation.
Bioprosthetic valve dysfunction provided a secondary out-
come. This was defined as any clinically relevant valvular
stenosis or insufficiency documented by Doppler echocardi-
ography, reoperation, or autopsy. For the purpose of these
evaluations, the date of reoperation, rather than the date of
echocardiographic confirmation of structural valve deteriora-
tion (SVD), was considered as the failure date in patients
with valve dysfunction. However, all patients who underwent
reoperation had Doppler echocardiography within 90 days of
their redo operation. We may, therefore, have slightly over-
estimated the time to SVD; however, we believe that this
method of ascertaining SVD would have contributed to noise,
rather than bias for subgroup comparisons. 
Additional outcomes included thromboembolic events
(only the first event being included in the analyses), biopros-
thetic valve endocarditis, and repeat AVR or MVR. 
Statistical analyses. SAS 6.12 for Windows was used for
statistical analyses (SAS Institute, Inc, Cary, NC).
Continuous variables are presented as mean ± standard error
unless otherwise noted. 
Univariate analysis. Differences in prognostic variables
between groups were evaluated by t tests for continuous vari-
ables and the χ2 or Fisher exact test for categoric variables. The
term actuarial is used in this report to describe the evaluation,
not the method, of time-related data. Time-related data such as
survival, freedom from reoperation, thromboembolic events,
SVD, or combined valve-related events were analyzed univari-
ately by the Kaplan-Meier method and the log-rank test. 
Actual versus actuarial freedom from SVD. Actual versus
actuarial freedom from SVD were also evaluated by methods
previously described by Grunkemeier and colleagues.5,6
Multivariable analysis. The preoperative variables tested
for their univariate and multivariable association with the out-
comes included age, sex, New York Heart Association
(NYHA) functional classification, left ventricular grade (1 =
ejection fraction > 60%, 2 = ejection fraction 40-60%, 3 =
ejection fraction 20-39%, 4 = ejection fraction < 20%), pre-
operative electrocardiographic rhythm (sinus, atrial fibrilla-
tion/flutter, heart block), endocarditis, CAD, valvular lesion
(stenosis, insufficiency, mixed), and previous cardiac opera-
tion. Patch aortic annuloplasty was tested in the multivariable
models for the aortic position. 
Operative death was evaluated multivariably by logistic
regression analysis and long-term outcomes were evaluated
by Cox regression analyses. For all multivariable models, the
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same model-building strategy was used: those variables with
a univariate P value < .25 or those of known biologic signif-
icance but failing to meet the critical α level were submitted
for consideration to regression analysis via the use of step-
wise selection, which combined forward selection with back-
ward elimination, to determine the independent, multivari-
able predictors of each outcome. Interactions with age were
tested in these models, but none was significant. The pres-
ence of CAD is a significant confounding factor in the evalu-
ation of survival after valve surgery. We have therefore pre-
sented a separate multivariable survival model for those
patients without CAD.
Results
Operative and late deaths. There were 32 (5%)
operative deaths in the AVR group and 25 (8%) opera-
tive deaths in the MVR group. Logistic regression
analysis revealed advanced NYHA classification (class
IV; odds ratio [OR]: 3.7; 95% confidence interval [CI]:
2.0-6.9), active endocarditis (OR: 3.9; 95% CI 1.6-9.1),
and the presence of concomitant CAD (OR: 2.5; 95%
CI 1.4-4.6) to be associated with an increased risk of
operative death in both groups. The area under the
receiver-operator-characteristic curve (discrimination)
for this model was 0.74; the Hosmer-Lemeshow good-
ness-of-fit P value was .5, indicating a significantly
precise model. Valve location was not predictive of
operative mortality. 
A summary of the causes of late death in both groups
is shown in Table III. There were 208 late deaths in the
AVR group and 124 late deaths in the MVR group.
Actuarial survival at 15 years was 47% ± 3% in the
AVR group and 30% ± 5% in the MVR group (Fig 1).
Among the late deaths in the AVR group, 28 (4%) were
valve-related, 81 (12%) were cardiac-related (non-
valve), and 96 (15%) were due to other causes. Among
the late deaths in the MVR group, 24 (8%) were valve-
related, 58 (19%) were cardiac-related, and 41 (13%)
were due to other causes. In 3 AVR patients and in 1
MVR patient, the exact cause of death was unknown. 
The 15-year actuarial survival after AVR for patients
less than 65 years of age was 65% ± 4% and for those
65 years of age or older, 30% ± 5% (P = .0001).
Preoperative NYHA functional class also emerged as
an important predictor of late survival. Patients with
symptoms at rest (class IV) demonstrated a 15-year
survival of only 36% ± 6%, whereas less symptomatic
patients (classes I, II, and III) demonstrated a long-term
survival of 52% ± 4% (P = .0001). Similarly, in patients
with grade 3 and 4 ventricles preoperatively, 15-year
survival was only 35% ± 6%, in comparison with those
patients with grade 1 and 2 ventricles for whom sur-
vival was 50% ± 4% (P = .0001). Finally, patients with-
out CAD had a 15-year survival of 54% ± 4%, where-
as those with CAD had a long-term survival of 38% ±
5% (P = .0001). 
Actuarial survival in patients after MVR who were
less than 65 years of age was 43% ± 8%; those 65 years
and older had a 15-year survival of only 20% ± 7% (P
= .002). MVR patients with symptoms at rest had a 15-
year survival of 15% ± 5%, compared with 45% ± 8%
Table I. Clinical profile of patients 
Variable AVR MVR
No. of patients 670 310
Age (y)
Mean 65 ± 12 65 ± 11
Range (18-86) (22-87)
Sex
Male 505 (75) 137 (44)
Female 165 (25) 173 (56)
Electrocardiogram
Sinus rhythm 599 (89) 155 (50)
Atrial fibrillation 51 (8) 138 (45)
Complete heart block 20 (3) 17 (5)
Infective endocarditis
Remote 11 (2) 10 (3)
Active 14 (2) 15 (5)
Active abscess 10 (1) 4 (1)
NYHA functional class
I 19 (3) 6 (2)
II 157 (23) 23 (8)
III 286 (43) 122 (39)
IV 208 (31) 159 (51)
Previous cardiac operation
CABG 20 (3) 25 (8)
AVR 45 (7) 5 (2)
MVR 0 42 (14)
Other 5 (1) 7 (2)
LVEF
LV grade 1 = EF >0.60 157 (23) 96 (31)
LV grade 2 = EF 0.40-0.59 271 (40) 125 (40)
LV grade 3 = EF 0.20-0.39 115 (17) 56 (18)
LV grade 4 = EF <0.20 28 (5) 15 (5)
Not available 99 (15) 18 (6)
CAD 297 (44) 139 (45)
Aortic valve lesion
Stenosis 316 (47) 0
Insufficiency 159 (24) 16 (5)
Mixed 191 (29) 2 (1)
Mitral valve lesion
Stenosis 1 (0.1) 56 (18)
Insufficiency 11 (2) 194 (63)
Mixed 0 57 (18)
Tricuspid valve disease 0 43 (14)
Numbers in parentheses are percentages unless otherwise specified. AVR,
Aortic valve replacement; MVR, mitral valve replacement; NYHA, New York
Heart Association functional class; CABG, coronary artery bypass grafting;
LV, left ventricular; EF, ejection fraction; CAD, coronary artery disease.
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(P = .0001) for those in NYHA classes I-III. Survival at
15 years in MVR patients with poor ventricular func-
tion was only 10% ± 8% compared with 36% ± 6% 
(P = .0001) for those with grade 1 or 2 left ventricular
function. The presence of CAD in MVR was associat-
ed with a 15-year survival of 20% ± 7%, whereas those
without CAD had a survival of 37% ± 7% (P = .003). 
Site-specific multivariable models are presented in
Tables IV (AVR) and V (MVR) for all-cause mortality,
mortality in patients without CAD, and thromboembol-
ic events. Because the number of events was relatively
small for SVD, reoperation, and valve-related mortality,
these multivariable models are presented in Table VI for
the combined AVR plus MVR data set. In these com-
bined models, valve site was included in the list of prog-
nostic variables submitted for consideration to the
analysis. 
Freedom from valve-related mortality at 15 years was
92% ± 2% in the AVR group and 86% ± 3% in the
MVR group. Preoperative atrial fibrillation and poor
left ventricular function were independently associated
with increased valve-related mortality (Table VI).
Thromboembolic events. There were no docu-
mented thromboses of the implanted Hancock bio-
prostheses in this series. Sixty (9%) late thromboem-
bolic events occurred in patients with AVR: 43
(6.5%) were defined as strokes and 17 (2.6%) as tran-
sient cerebral ischemic attacks. Ten (23%) of the
strokes were fatal. Twenty-three (8%) late throm-
boembolic events occurred in patients with MVR: 20
(6.5%) were defined as strokes and 3 (1.0%) as tran-
sient cerebral ischemic attacks. Nine (45%) of the
strokes were fatal. The actuarial freedom from
thromboembolic events at 15 years was 83% ± 3% in
the AVR group and 87% ± 3% in the MVR group.
Advanced age and preoperative atrial fibrillation
were associated with an increased risk of throm-
boembolic events by Cox regression analysis.
Bioprosthetic valve endocarditis. Bioprosthetic
valve endocarditis developed in 18 (2.7%) patients in
the AVR group. Antibiotic therapy along with reopera-
tion was undertaken in 7 patients, all of whom survived.
The remaining 11 patients, none of whom survived,
were treated conservatively. Nine of these patients were
deemed to have inoperable disease because of one of
more of the following factors: advanced age, poor ven-
tricular function, multiorgan failure, or previous com-
plex operation for endocarditis with multiple abscesses.
In 2 patients the diagnosis of prosthetic valve endo-
carditis was established at autopsy. Bioprosthetic valve
endocarditis developed in 11 (3.6%) patients in the
MVR group. Antibiotic therapy along with reoperation
was undertaken in 4 patients, all of whom survived. The
remaining 7 patients, none of whom survived, were
Table II. Operative data
Variable AVR MVR
No. of patients 670 310
Tricuspid valve repair 1 (0.1) 35 (11)
Enlargement of aortic anulus 125 (19) 0
Replacement of ascending aorta 78 (12) 3 (1)
Coronary artery bypass 294 (43) 127 (41)
AVR: Hancock II size
21 48 (7) 0
23 198 (30) 0
25 208 (31) 0
27 174 (26) 0
29 42 (6) 0
MVR: Hancock II size
25 0 11 (4)
27 0 64 (21)
29 0 91 (29)
31 0 113 (36)
33 0 31 (10)
Aortic crossclamp time, min (mean ± SD) 73 ± 27 67 ± 27
CPB time, min (mean ± SD) 99 ± 36 95 ± 37
Operative mortality 32 (4.8) 25 (8)
Numbers in parentheses are percentages unless otherwise specified. AVR,
Aortic valve replacement; MVR, mitral valve replacement; SD, Standard devi-
ation; CPB, cardiopulmonary bypass.
Table III. Summary of late morbidity and mortality
Variable AVR MVR
Late deaths 208 (31) 124 (40)
Causes of late death
Valve-related 28 (4) 24 (8)
Cardiac (non-valve related) 81 (12) 58 (19)
Non-cardiac/Non-valve 96 (15) 41 (13)
Unknown 3 (0.4) 1 (0.3)
SVD 23 (3) 26 (9)
Thromboembolism
Stroke 43 (7) 20 (7)
TIA 17 (3) 3 (1)
Reoperation at follow-up 38 (6) 28 (9)
Prosthetic valve endocarditis 18 (3) 11 (4)
Valve-related morbidity/mortality 120 (18) 74 (24)
AVR, Aortic valve replacement; MVR, mitral valve replacement; SVD, struc-
tural valve deterioration; TIA, transient ischemic attack; Late deaths, all
deaths excluding operative deaths; Valve-related deaths, death from SVD,
stroke, TIA, prosthetic valve endocarditis, reoperation on the bioprosthetic
valve, anticoagulant-related hemorrhage, valve thrombosis, or hemolysis;
Cardiac deaths, death from ischemic heart disease, congestive heart failure, or
sudden death; Valve-related morbidity/mortality, morbidity or mortality
caused by primary tissue failure, stroke, TIA, prosthetic valve endocarditis,
reoperation on bioprosthetic valve, anticoagulant-related hemorrhage, valve
thrombosis, or hemolysis.
272 David et al The Journal of Thoracic and
Cardiovascular Surgery
February 2001
treated conservatively because they were deemed to
have inoperable disease. The actuarial freedom from
endocarditis at 15 years was 96% ± 1% in the AVR
group and 91% ± 4% in the MVR group. Preoperative
atrial fibrillation was the only variable that was predic-
tive of endocarditis (RR = 2.4; 95% CI = 1.1–5.1; P =
.02). However, because of the relatively small number
of events for this outcome, there is a very real potential
for making a type II statistical error.
SVD. Bioprosthetic valve dysfunction due to SVD
occurred in 49 patients. Of the 23 patients with SVD in
the AVR group, only 1 (0.2%) was 65 years of age or
older. Conversely, of the 26 patients with SVD in the
MVR group, 8 (5.0%) were 65 years of age or older.
All but 1 patient with SVD in the AVR group under-
went reoperation, whereas 21 of the 26 patients with
SVD in the MVR group underwent reoperation. The
actuarial freedom from SVD at 15 years was 81% ± 5%
in the AVR group and 66% ± 6% in the MVR group
(Fig 2). Younger age, the mitral valve position, and
poor ventricular function were independently predic-
tive of SVD (Table VI).
Fig 1. Actuarial (Kaplan-Meier) survival.
Table IV.  Multivariable predictors of outcomes in the aortic position
Predictor Risk ratio 95% CI χ2 P value
All mortality
NYHA class IV 1.5 1.1, 2.0 28 0
Age (per 5-year increase) 1.2 1.1, 1.2 18.2 0
CAD 1.4 1.1, 1.8 7.2 .007
Active endocarditis 2.6 1.4, 4.8 7.1 .008
LVEF < 40% 1.5 1.1, 2.1 7.8 .005
Mortality in patients without CAD
Preop AF 3.4 1.9, 6.1 19 0
LVEF < 40% 2.1 1.4, 3.3 15 0
Active endocarditis 4.0 1.8, 8.8 14 0
Age (per 5-year increase) 1.1 1.0, 1.2 5.6 .018
Male sex 1.9 1.2, 2.9 7.3 .007
Thromboembolic events
Age (per 5-year increase) 1.2 1.0, 1.3 6.7 .009
Preop AF 2.1 1.0, 4.6 4.1 .042
CI, Confidence interval; NYHA, New York Heart Association classification; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; Preop AF, preop-
erative atrial fibrillation.
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Fig 3 shows the actual freedom from SVD in the AVR
group. At 15 years the actual freedom from SVD was
90% ± 3%; however, in patients less than 65 years of age
it was 76% ± 6%, whereas in patients 65 years of age or
older it was 100%. Fig 4 shows the actual freedom from
SVD in the MVR group. At 15 years the actual freedom
from SVD was 83% ± 3%; however, in patients less than
65 years of age it was 76% ± 5%, whereas in patients 65
years of age or older it was 89% ± 4%. 
Reoperation. Sixty-six patients underwent repeat
valve replacement at the time of follow-up (38 AVR:
6%; 28 MVR: 9%) (Table III). The rate of reoperation
was significantly higher in younger patients regardless
of valve site. The indications for reoperation in the
AVR group included ascending aortic aneurysm (2
patients), aortic dissection (1 patient), CAD (1 patient),
patient-prosthesis mismatch with high systolic gradient
with a normal valve (1 patient), SVD (22 patients),
paravalvular leak (3 patients), bioprosthetic valve
endocarditis (7 patients), and recurrent transient
ischemic attacks (1 patient). There were no deaths
among the 38 patients who had repeat AVR. The indi-
cations for reoperation in the MVR group were AVR (1
patient), paravalvular leak (2 patients), bioprosthetic
valve endocarditis (4 patients), and SVD (21 patients).
One patient in the MVR group underwent heart trans-
plantation. Only 1 death was caused by reoperation in
the MVR group. The actuarial freedom from reopera-
tion at 15 years was 77% ± 5% in the AVR group and
69% ± 6% in the MVR group (Fig 5). Cox regression
Fig 2. Actuarial (Kaplan-Meier) freedom from SVD. AV, Aortic valve; MV, mitral valve.
Table V. Multivariable predictors of outcomes in the mitral position
Predictor Risk ratio 95% CI χ2 P value
All mortality
NYHA class IV 1.9 1.4, 2.8 30 0
Age (per 5-year increase) 1.3 1.2, 1.4 17 0
LVEF < 40% 2.2 1.5, 3.1 16 0
Active endocarditis 2.7 1.4, 5.2 9 .003
Mortality in patients without CAD
Age (per 5-year increase) 1.5 1.3, 1.8 29 0
Active endocarditis 3.9 1.9, 8.2 14 0
LVEF < 40% 2.0 1.0, 4.1 3.9 .049
Thromboembolic events
Age (per 5-year increase) 1.2 1.0, 1.3 6.7 .009
Preop AF 2.1 1.0, 4.6 4.1 .042
CI, Confidence interval; NYHA, New York Heart Association classification; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; Preop AF, pre-
operative atrial fibrillation.
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analysis revealed younger age and poor ventricular
function as independent predictors of reoperation
(Table VI).
Hemorrhagic complications. Fifty-seven patients
who had undergone AVR were taking warfarin sodi-
um at the last follow-up contact because of atrial fib-
rillation or a previous stroke. Three of these patients
had serious hemorrhagic complications. Sixty-nine
patients who underwent MVR were taking warfarin
sodium: 8 had serious hemorrhagic complications and
2 of them died. 
Overall valve-related morbidity or mortality. The
overall freedom from any valve-related morbidity or
mortality at 15 years was 59% ± 5% in the AVR group
and 48% ± 6% in the MVR group. Preoperative atrial
fibrillation and poor ventricular function were predic-
tive of valve-related morbidity or mortality (Table VI).
Late NYHA functional classification. At the time
of last follow-up, 517 (53%) patients were alive with
their original Hancock II bioprostheses (387 AVR, 130
MVR). Among those who underwent AVR, 52% were
in NYHA functional class I, 30% were in class II,
17.7% were in class III, and 0.8% were in class IV.
Only 1 patient in classes III or IV had echocardio-
graphic evidence of bioprosthetic aortic valve dysfunc-
tion (this patient was included in the analysis for SVD).
Among those who underwent MVR, 38% were in
NYHA functional class I, 35% were in class II, and
Fig 3. Actual freedom from SVD after AVR.
Table VI. Multivariable predictors of outcomes in combined data for both aortic and mitral positions
Predictor Risk ratio 95% CI χ2 P value
Structural valve deterioration
Age (per 5-year increase) 0.8 0.7, 0.9 21 0
Mitral position 2.2 1.2, 3.9 8.3 .004
LVEF <40% 2.0 1.0, 4.0 4.2 .04
Reoperation
Age (per 5-year increase) 0.7 0.7, 0.8 56 0
LVEF < 40% 1.9 1.1, 3.5 4.9 .027
Valve-related mortality
Age (per 5-year increase) 1.4 1.1, 1.6 13 0
Preop AF 2.1 1.2, 3.8 7.6 .006
Active endocarditis 3.2 1.0, 10 4.1 .043
Valve-related morbidity or mortality
Preop AF 1.7 1.2, 2.4 8.8 .003
LVEF < 40% 1.5 1.1, 2.2 5.4 .02
CI, Confidence interval; LVEF, left ventricular ejection fraction; Preop AF, preoperative atrial fibrillation.
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27% were in class III. Five patients in class III had
echocardiographic evidence of bioprosthetic mitral
valve dysfunction. 
Discussion
The hemodynamic and clinical outcomes of valve
replacement with the Hancock II bioprosthesis have
been previously reported by our group.2,7,8 We present an
update of our experience with this prosthesis in response
to its recent approval for use in the United States.
Although numerous factors affect long-term survival
after AVR, hemodynamic performance of the valve
may also play a significant role. We believe that high
transvalvular gradients across the aortic valve have
adverse effects on the patients’ symptoms, ventricular
function, and ultimately survival. The 15-year survival
of our patients who had AVR was better than that of
other series of patients with similar age and risk fac-
tors.9-14 Indeed, a report by Ikonomidis and colleagues9
documented better long-term survival after AVR in
patients with Hancock II bioprostheses than in patients
with the standard Hancock valve. We believe that the
hemodynamic performance of the Hancock II valve
coupled with patch enlargement of the aortic anulus
Fig 4. Actual freedom from SVD after MVR.
Fig 5. Actuarial (Kaplan-Meier) freedom from repeat valve replacement. AV, Aortic valve; MV, mitral valve.
attempt to model this outcome should be interpreted
with caution; we may have missed some important pre-
dictors of prosthetic valve endocarditis due to the small
number of events.
Age and valve position have been shown to be the
most powerful determinants of bioprosthetic valve
longevity, with increased durability in the aortic posi-
tion of elderly patients.8,10-14 Accordingly, in our
series the Hancock II bioprosthesis was found to be
more durable in the aortic than in the mitral position.
This difference in durability may be due to elevated
closing pressures and, thus, increased hemodynamic
stresses in the mitral position.10 Older patients who
had AVR with the Hancock II prosthesis were unlike-
ly to outlive their bioprosthetic valve. In fact, only 1
of the 23 documented cases of SVD in the AVR group
occurred in a patient who was 65 years of age or older.
Conversely, 8 of the 26 cases of SVD in the MVR
group occurred in patients 65 years of age or older.
Therefore, our presentation of actual freedom from
SVD using the age cut-point of less than or greater
than 65 years (Figs 3 and 4) is for illustrative purpos-
es only. In our multivariable models of SVD, we used
age as a continuous variable and found that younger
age, as well as the mitral site and ventricular dysfunc-
tion, were independently associated with an increased
risk of SVD. The actual freedom from SVD at 15
years was 90% in the AVR group and 83% in the
MVR group. Valves in the mitral position began to fail
6 years postoperatively, whereas valves in the aortic
position did not begin to fail until 9 years postopera-
tively. Although younger patients had a higher prevalence
of reoperation at follow-up, they did not demonstrate an
increased frequency of valve-related deaths, owing in
large part to the fact that all but 1 patient with SVD
underwent successful reoperations.
A comparison of clinical outcomes of patients who
had Hancock bioprostheses demonstrated the Hancock
II model to be a more durable porcine valve.9 This dif-
ference is likely due to improved stent design and
porcine aortic valve treatment.1 The Hancock II valve
is at least as durable as the second-generation pericar-
dial valves such as the Carpentier-Edwards Perimount
prosthesis (Baxter Healthcare Corp, Edwards Division,
Santa Ana, Calif).13,14 Banbury and colleagues14
reported an actuarial freedom from SVD at 12 years of
82% after AVR with the Carpentier-Edwards pericar-
dial valve in a patient-population whose mean age was
65 years. Poirier and colleagues13 reported an actuarial
freedom from SVD at 14 years of 80% after AVR. The
freedom from SVD in our patients who had AVR was
better than in those two reports in a patient population
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used to avoid patient-prosthesis mismatch played a role
in the difference of outcomes. The smallest Hancock II
bioprosthesis available for AVR is size 21, and its
effective orifice area is 1.1 to 1.2 cm2.2 For this reason,
we believe this size of valve should not be implanted in
a patient with a body surface area larger than 1.6 m2 if
patient-prosthesis mismatch is to be avoided.2,15
Similarly, a Hancock II size 23 (effective orifice area of
1.3 to 1.4 cm2) should not be implanted in a patient
with a body surface area larger than 1.7 m2. To avoid
patient-prosthesis mismatch, 19% of our AVR patients
had patch enlargement of the aortic anulus. As seen in
Table II, only 7% of our patients had size 21 valves.
Patch enlargement of the aortic anulus was not per-
formed in these patients because their anuli could not
accommodate a size 21 Hancock II bioprosthesis. Patch
enlargement of the aortic anulus was not an indepen-
dent predictor of any adverse event in our multivariable
models. High gradients across bioprosthetic heart
valves can also be a problem after MVR. A Hancock II
bioprosthesis smaller than size 27 should not be
implanted in the mitral position of adult patients. In this
series, 11 patients had MVR with valve size 25 and
none of 10 operative survivors were in NYHA func-
tional class I postoperatively.
Long-term survival after AVR or MVR is highly
dependent on the patients’ ages and comorbid condi-
tions.16,17 Multivariable analysis revealed that
advanced age, NYHA functional class IV, left ventric-
ular ejection fraction below 40%, and active endocardi-
tis were independent predictors of late mortality after
AVR or MVR in our series. CAD was also a predictor
of late mortality in the AVR group. According to a pre-
vious report by our group, as the number of the afore-
mentioned risk factors increases, the long-term survival
decreases after AVR.18 These variables are important to
aid the surgeon in discussions with the patient about
the most appropriate type of heart valve prosthesis for
AVR or MVR and to estimate the probability of reop-
eration for SVD. 
The rates of thromboembolic events and infective
endocarditis after AVR or MVR with the Hancock II
bioprosthesis are similar to those reported for other
stented porcine and pericardial valves.10-14,18 We found
that advanced age and atrial fibrillation increased the
risk of thromboembolic events in both the AVR and
MVR groups.
Bioprosthetic valve endocarditis was an uncommon
but extremely serious valve-related complication in this
series. The risk of endocarditis was highest during the
first year after the operation and then decreased to a
low but constant risk in both groups of patients. Our
11. Glower DD, Landolfo KP, Cheruvu S, Cen YY, Harrison JK,
Bashore TM, et al. Determinants of 15-year outcome with 1119
standard Carpentier-Edwards porcine valves. Ann Thorac Surg
1998;66:S44-8.
12. Jamieson WRE, Burr LH, Munro AI, Miyagishima RT.
Carpentier-Edwards standard porcine bioprosthesis: a 21 year
experience. Ann Thorac Surg 1998;66:S40-3.
13. Poirier NC, Pelletier LC, Pellerin M, Carrier M. 15-year experi-
ence with the Carpentier-Edwards pericardial bioprosthesis. Ann
Thorac Surg 1998;66:S57-61.
14. Banbury MK, Cosgrove DM III, Lytle BW, Smedira NG, Sabik
JF, Saunders CR. Long-term results of the Carpentier-Edwards
pericardial aortic valve: a 12-year follow-up. Ann Thorac Surg
1998;66:S73-6.
15. Dumesnil JG,Yoganathan A. Valve prosthesis hemodynamics and
the problem of high transprosthetic pressure gradients. Eur J
Cardiothorac Surg 1992;6(suppl 1):534-7.
16. Jones EL, Weintraub WS, Craver JM, Guyton RA, Shen Y.
Interaction of age and coronary artery disease after valve replace-
ment: implications for valve selection. Ann Thorac Surg
1994;58:378-85.
17. Cohen G, David TE, Ivanov J, Armstrong S, Feindel CM. Impact
of coronary artery disease, age, and other comorbid factors on
late outcome after bioprosthetic aortic valve replacement. J
Thorac Cardiovasc Surg 1999;117:273-84. 
18. Marchand M, Aupart M, Norton R, Goldsmith IR, Pelletier C,
Pellerin M, et al. Twelve-year experience with Carpentier-
Edwards Perimount pericardial valve in the mitral position: a
multicenter study. J Heart Valve Dis 1998;7:292-8.
Discussion
Dr W. R. Eric Jamieson (Vancouver, British Columbia,
Canada). I congratulate you on an excellent series of patients
and excellent analysis. Your conclusions are that this second-
generation, supra-annular, essentially low-pressure fixed bio-
prosthesis is providing extended durability, particularly in the
aortic position and particularly in patients who are older than
65 years of age. These are not necessarily all elderly as we
probably classify them today; age 75 years is probably now
considered elderly. 
One of the important aspects of this series is that it can
serve as a benchmark for comparison not only with the first-
generation bioprostheses, but also with other second-genera-
tion bioprostheses, namely, the Edwards Supra-Annular bio-
prosthesis (Baxter) and the St Jude Medical Biocor
bioprosthesis (St Jude Medical, Inc, St Paul, Minn). This will
allow us to determine those factors that are improved in these
prostheses that will contribute to improved durability. Is it tis-
sue preservation? Is it stent design? These are very important
factors with regard to improved durability. 
The other important contribution is that the authors have
used the cumulative incidence, or actual analysis, looking
particularly at SVD. This method has been popularized by Dr
Gary Grunkemeier from Portland in collaboration with
Stanford University and the University of British Columbia.
This method provides a more realistic evaluation of the influ-
ence of SVD on overall valve performance and information
that can be supplied to patients. 
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of similar age. In the mitral position, the freedom from
SVD for the Carpentier-Edwards pericardial valve was
81% ± 7% at 10 years in the series reported by Poirier
and associates13 and approximately 85% in a multicen-
ter study reported by Marchand and colleagues.18 The
freedom from SVD in the mitral position in our series
was similar to those reported for the Carpentier-
Edwards pericardial valve.
Although this study confirms the favorable late
results of the Hancock II bioprosthesis at our institu-
tion, its inherent limitations are those that apply to any
observational outcomes analysis. Event rates were rel-
atively small for some outcomes, which jeopardized the
statistical power of some of our multivariable models
(for example, we may have failed to identify an impor-
tant predictor variable as significant). Nonetheless, the
clinical outcomes with this bioprosthetic valve were
very good. Furthermore, the durability of the Hancock
II valve has been excellent, particularly in the aortic
position and in patients 65 years of age or older. In
view of the aforementioned, the Hancock II biopros-
thesis offers an excellent option for tissue valve
replacement. 
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a number of design alterations aimed at improving its overall
performance in comparison to the Hancock I. These include
the use of a stent manufactured from the polymer Delrin,
which is more flexible, more durable, and more creep resis-
tant than previous stents; the application of the calcium retar-
dant T6; the new supra-annular design; and the removal of the
porcine septal muscle shelf to maximize the area available for
flow. Now, can such findings be extrapolated to conclude a
superiority of the Hancock II over other second-generation
valves? Obviously not. This can only be determined with a
properly designed study involving a head-to-head compari-
son of similar patient groups.
Dr Verdi DiSesa (Chicago, Ill). Did you use anticoagu-
lants in any of these patients? 
Dr Cohen. Until 1989, all of our patients undergoing bio-
prosthetic AVR and MVR received warfarin sodium
(Coumadin) for 3 months postoperatively, after which war-
farin was discontinued and antiplatelet therapy initiated. This
practice changed in 1990, such that AVR patients no longer
received warfarin, whereas MVR continued receiving war-
farin for 3 months. Currently, the bioprosthetic AVR patients
receive only antiplatelet therapy, which is usually initiated on
the first postoperative day, unless, of course, other indications
for warfarin therapy exist, such as atrial fibrillation. 
Dr DiSesa. How many had chronic atrial fibrillation and
therefore had long-term anticoagulation? 
Dr Cohen. Unfortunately, I cannot recall the exact num-
bers. However, I would say that the percentage of patients
with chronic atrial fibrillation was in the range of 10% in the
AVR group and 45% in the MVR group.
Dr DiSesa. My patients whose mitral valves cannot be
repaired usually have atrial fibrillation or other conditions
requiring anticoagulation. Therefore, the old-style pig valves
for MVR are not often an option. Do you think this valve has
been incrementally improved enough, especially in the
younger patients, that it is a real option for MVR? 
Dr Cohen. Regarding the superiority of the Hancock II
valve in the mitral position, I can only comment on improve-
ments with respect to the Hancock I valve. In our collabora-
tive studies with the Stanford group, although the Hancock II
cohort had a higher prevalence of older patients, as well as
patients in preoperative NYHA functional class IV, use of the
Hancock I valve was found to be the most significant inde-
pendent predictor of SVD and death. Moreover, propensity
scores suggested an improved durability of the Hancock II
mitral valve versus the Hancock I mitral valve. We do indeed
believe that this valve is incrementally superior in the mitral
position.
278 David et al The Journal of Thoracic and
Cardiovascular Surgery
February 2001
I have a few comments and questions.
Have you considered using the actual method to look at
valve-related mortality and morbidity—not as you have
defined morbidity, but rather as permanent impairment from
thromboembolism, endocarditis, or hemorrhage—also valve-
related reoperation? It is conceivable that this kind of infor-
mation is most important for us as surgeons, for our cardiol-
ogy colleagues, and specifically for our patients. The patients
want to know their risk of dying from this valve, of sustain-
ing permanent impairment, and of requiring reoperation.
Our group is currently collaborating with Dr David’s to
assess some of my concerns regarding this prosthesis and its
contribution in conjunction with our experience with second-
generation prostheses. This study will also serve as a land-
mark for the current third-generation prostheses and the
stented bioprostheses and their contributions in improving
clinical performance and durability of prostheses. 
Dr Cohen. Thank you very much, Dr Jamieson. I will
address your second comment first. I agree with you com-
pletely regarding the merits of an actual versus an actuarial
analysis. As you alluded to in your discussion, the actual risk
or cumulative incidence is likely of greater relevance to both
patients and surgeons alike. Since it is often not possible to
follow up all patients until their death, the actuarial method
estimates the event-free probability for a population in which
death has been completely eliminated. However, what is of
great interest for counseling purposes, as well as for expense
planning, is the risk of an event occurring during the lifetime
of a patient. For the purposes of this article, we chose only to
analyze freedom from SVD via this method. However, I
agree that application of such an analytical method to other
parameters including thromboembolic complications, hemor-
rhagic complications, endocarditis, and reoperation is equal-
ly important. Perhaps we will pursue this in the future. With
regard to your comments concerning a comparison with other
second-generation porcine valves including the SAV, I think
you will agree that the Hancock II valve is to the Hancock
valve what the Carpentier-Edwards SAV is to the CE
Standard valve, namely, an improved version of a first-gener-
ation porcine valve. However, in contrast to reports from your
group, in which you found no differences in durability
between the SAV and Standard valves at 15 years, in a col-
laborative effort with Dr Craig Miller’s group in Stanford, we
were able to demonstrate a dramatic improvement in freedom
from SVD, reoperation, and valve-related morbidity and mor-
tality with the Hancock II versus the Hancock I valve.
Although the factors contributing to this profound improve-
ment are difficult to ascertain, the Hancock II has undergone
